Clinical trials: Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
- Trial name
- NCT06194799
- Testing
- ACP-204
- Where
- 78 sites in United States, Brazil and 10 more
- Volunteers
- 752 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute